MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors - Scorecard - MDSpire

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • May 7, 2026

  • 4 min

Share

Clinical Scorecard: MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

At a Glance

CategoryDetail
ConditionMetastatic Neuroendocrine Tumors (NETs)
Key MechanismsSurVaxM is a peptide vaccine targeting the protein survivin, which may block tumor growth and elicit an immune response.
Target PopulationPatients with progressing metastatic neuroendocrine tumors.
Care SettingRoswell Park Comprehensive Cancer Center, Buffalo, New York.

Key Highlights

  • Phase 2 trial evaluates SurVaxM combined with temozolomide versus temozolomide alone.
  • SurVaxM has shown safety and immune response in prior phase 1 trials.
  • Approximately 52% of NET specimens express survivin, correlating with aggressive tumor behavior.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of NETs based on clinical evaluation and imaging studies.

Management

  • Consideration of SurVaxM in combination with temozolomide for patients progressing on first-line therapy.

Monitoring & Follow-up

  • Monitor for immune responses and clinical benefits in patients receiving SurVaxM.

Risks

  • Potential adverse effects associated with immunotherapy and chemotherapy.

Patient & Prescribing Data

Patients diagnosed with metastatic neuroendocrine tumors.

SurVaxM may provide a new treatment option for patients with limited options after first-line therapy.

Clinical Best Practices

  • Engage in collaborative research to explore new treatment options for NETs.
  • Utilize immunotherapy approaches targeting survivin in eligible patients.

Related Resources & Content

Original Source(s)

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

  • May 7, 2026

Related Content

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
Baptist Health Cancer Care to Present Research on Precision Radiation Therapy Across Complex Cancers at ASTRO 2026

Experts across Baptist Health Herbert Wertheim Cancer Institute and Eugene M. & Christine E. Lynn Cancer Institute will present new radiation oncology research and clinical expertise at the 2026 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 26-30, 2026, in Boston.

  • by

  • July 7, 2026

  • 8 min
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min